Skip to main content

Table 3 Patient demographics and clinical characteristics

From: Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan

  Global
(n = 1195)
UK
(n = 127)
France
(n = 254)
Germany
(n = 179)
Italy
(n = 155)
Spain
(n = 173)
EU5
(n = 888)
Japan
(n = 125)
US
(n = 182)
Age, mean, years (SD) 72.1 (8.01) 70.7 (7.75) 73.7 (7.97) 70.3 (6.82) 73.7 (8.10) 71.3 (8.08) 72.1 (7.89) 75.3 (7.46) 69.4 (8.10)
Employment status at time of data collection, n (%)          
 Working 158 (13.2) 24 (18.9) 5 (2.0) 11 (6.1) 17 (11.0) 12 (6.9) 69 (7.8) 27 (21.6) 62 (34.1)
 Not working 1015 (84.9) 102 (80.3) 247 (97.2) 168 (93.9) 132 (85.2) 157 (90.8) 806 (90.8) 90 (72) 119 (65.4)
 Don’t know 22 (1.8) 1 (0.8) 2 (0.8) 0 (0.0) 6 (3.9) 4 (2.3) 13 (1.5) 8 (6.4) 1 (0.5)
ECOG performance status at time of data collection, n (%)          
 0–1 941 (78.7) 111 (87.4) 186 (73.2) 118 (65.9) 125 (80.6) 152 (87.9) 692 (77.9) 114 (91.2) 135 (74.2)
 2–4 248 (20.8) 16 (12.6) 64 (25.2) 61 (34.1) 28 (18.1) 21 (12.1) 190 (21.4) 11 (8.8) 47 (25.8)
 Unknown/not assessed 6 (0.5) 0 (0.0) 4 (1.6) 0 (0.0) 2 (1.3) 0 (0.0) 6 (0.7) 0 (0.0) 0 (0.0)
Disease status at time of data collection, n (%) 1189 126 252 178 153 173 882 125 182
 Disease progressing 55 (4.6) 1 (0.8) 2 (0.8) 29 (16.3) 3 (2.0) 7 (4.0) 42 (4.8) 3 (2.4) 10 (5.5)
 Stable 444 (37.3) 19 (15.1) 76 (30.2) 76 (42.7) 66 (43.1) 53 (30.6) 290 (32.9) 75 (60) 79 (43.4)
 Responding to treatment 690 (58.0) 106 (84.1) 174 (69.0) 73 (41.0) 84 (54.9) 113 (65.3) 550 (62.4) 47 (37.6) 93 (51.1)
Patient’s family history of prostate cancer, n (%) 1195 127 254 179 155 173 888 125 182
 Has a family history 111 (9.3) 9 (7.1) 18 (7.1) 30 (16.8) 8 (5.2) 17 (9.8) 82 (9.2) 5 (4.0) 24 (13.2)
 Does not have a family history 997 (83.4) 106 (83.5) 224 (88.2) 142 (79.3) 130 (83.9) 150 (86.7) 752 (84.7) 99 (79.2) 146 (80.2)
 Don’t know 87 (7.3) 12 (9.4) 12 (4.7) 7 (3.9) 17 (11.0) 6 (3.5) 54 (6.1) 21 (16.8) 12 (6.6)
Sites of metastases at time of data collection, n (%)          
 Bone 1020 (85.4) 118 (92.9) 239 (94.1) 136 (76) 135 (87.1) 160 (92.5) 788 (88.7) 109 (87.2) 123 (67.6)
 Brain 8 (0.7) 1 (0.8) 1 (0.4) 3 (1.7) 0 (0.0) 0 (0.0) 5 (0.6) 1 (0.8) 2 (1.1)
 Lung 97 (8.1) 12 (9.4) 25 (9.8) 11 (6.1) 10 (6.5) 17 (9.8) 75 (8.4) 5 (4.0) 17 (9.3)
 Pancreas 4 (0.3) 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.1) 0 (0.0) 3 (1.6)
 Liver 73 (6.1) 7 (5.5) 25 (9.8) 11 (6.1) 6 (3.9) 11 (6.4) 60 (6.8) 1 (0.8) 12 (6.6)
 Adrenal glands 17 (1.4) 0 (0.0) 5 (2.0) 4 (2.2) 2 (1.3) 3 (1.7) 14 (1.6) 1 (0.8) 2 (1.1)
 Peritoneal 30 (2.5) 0 (0.0) 5 (2.0) 10 (5.6) 2 (1.3) 0 (0.0) 17 (1.9) 0 (0.0) 13 (7.1)
Non-regional/distant lymph nodes 368 (30.8) 38 (29.9) 86 (33.9) 57 (31.8) 55 (35.5) 63 (36.4) 299 (33.7) 23 (18.4) 46 (25.3)
 Other 6 (0.5) 0 (0.0) 1 (0.4) 1 (0.6) 0 (0.0) 1 (0.6) 3 (0.3) 0 (0.0) 3 (1.6)
Number of bone metastases sites identified, n (%) 850 76 209 117 111 139 652 94 104
 1–3 lesions 435 (51.2) 36 (47.4) 104 (49.8) 60 (51.3) 54 (48.6) 60 (43.2) 314 (48.2) 57 (60.6) 64 (61.5)
 4 + lesions 415 (48.8) 40 (52.6) 105 (50.2) 57 (48.7) 57 (51.4) 79 (56.8) 338 (51.8) 37 (39.4) 40 (38.5)
Risk status, n (%)          
 Low-risk 674 (56.4) 58 (45.7) 133 (52.4) 115 (64.2) 94 (60.6) 89 (51.4) 489 (55.1) 55 (44.0) 130 (71.4)
 High-risk 433 (36.2) 49 (38.6) 103 (40.6) 54 (30.2) 44 (28.4) 78 (45.1) 328 (36.9) 60 (48.0) 45 (24.7)
 Don’t know 88 (7.4) 20 (15.7) 18 (7.1) 10 (5.6) 17 (11.0) 6 (3.5) 71 (8.0) 10 (8.0) 7 (3.8)
Disease volume, n (%)          
 Low volume 598 (50.0) 50 (39.4) 117 (46.1) 102 (57.0) 67 (43.2) 76 (43.9) 412 (46.4) 77 (61.6) 109 (59.9)
 High volume 409 (34.2) 34 (26.8) 104 (40.9) 54 (30.2) 58 (37.4) 75 (43.4) 325 (36.6) 33 (26.4) 51 (28.0)
 Don’t know 188 (15.7) 43 (33.9) 33 (13.0) 23 (12.8) 30 (19.4) 22 (12.7) 151 (17.0) 15 (12.0) 22 (12.1)
Most recent PSA result at time of data collection (ng/mL), n 1037 101 215 158 139 161 774 116 147
 Mean (SD) 20.1 (60.42) 30.8 (81.17) 26.5 (70.03) 20.8 (67.75) 11.3 (17.84) 18.4 (38.90) 21.5 (59.59) 7.4 (20.95) 22.7 (81.32)
Most recent haemoglobin test result at time of data collection (g/dL), n 615 66 116 74 87 133 476 79 60
 Mean (SD) 12.0 (1.48) 11.7 (1.44) 12.3 (1.29) 11.8 (1.71) 11.8 (1.29) 12.0 (1.44) 12.0 (1.44) 12.3 (1.36) 12.3 (1.87)
Most recent alkaline phosphatase result at time of data collection (U/L), n 539 65 99 42 71 115 392 93 54
 Mean (SD) 196.8 (141.55) 179.2 (118.50) 181.5 (132.55) 162.0 (94.58)  209.2 (187.94)  189.2 (134.52)  186.3 (139.34) 256.8 (146.57)   169.3 (115.83)
  1. ECOG Eastern Cooperative Oncology Group, EU5 France, Germany, Italy, Spain, and the United Kingdom, PSA prostate-specific antigen, SD standard deviation, UK United Kingdom, US United States